# Osmotica Pharmaceuticals plc (OSMT)

Source: https://www.quantisnow.com/company/OSMT
Generated: 2026-11-14T17:46:51.168Z

- Ticker: OSMT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2018
- Website: osmotica.com

## About

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

## Latest OSMT news and filings

- 2022-01-19 15:53 UTC [Market Insight] [Osmotica Pharma Announces Rebranding As RVL Pharma, Issues Q4 Sales Outlook](https://www.quantisnow.com/insight/osmotica-pharma-announces-rebranding-as-rvl-pharma-issues-q4-sales-2271478)
- 2022-01-19 12:07 UTC [SEC Form 8-K] [Osmotica Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-plc-filed-sec-form-8-k-results-of-operations-2269312)
- 2022-01-19 11:50 UTC [Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol "RVLP," Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-plc-announces-corporate-name-change-to-rvl-pharmaceuticals-2269115)
- 2022-01-19 11:53 UTC [Market Insight] [Osmotica Pharmaceuticals Says Q4 Net Sales For UNPEEQ Targeted To Range From $20M-$25M](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-says-q4-net-sales-for-unpeeq-targeted-to-2269104)
- 2022-01-19 11:51 UTC [Market Insight] [Osmotica Pharmaceuticals Announces Corporate Name Change to RVL Pharmaceuticals plc With New Ticker Symbol 'RVLP'](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-announces-corporate-name-change-to-rvl-pharmaceuticals-plc-2269099)
- 2022-01-18 13:16 UTC [SEC Form 8-K] [Osmotica Pharmaceuticals plc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-plc-filed-sec-form-8-k-amendments-to-articles-2263090)
- 2022-01-18 11:50 UTC [RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022](https://www.quantisnow.com/insight/rvl-pharmaceuticals-to-host-upneeq-overview-and-business-update-webcast-2262025)
- 2022-01-06 13:55 UTC [Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-plc-to-host-upneeq-overview-and-business-update-2222516)
- 2021-12-27 10:07 UTC [Market Insight] [54 Biggest Movers From Thursday](https://www.quantisnow.com/insight/54-biggest-movers-from-thursday-2183087)
- 2021-12-23 17:00 UTC [Market Insight] [38 Stocks Moving In Thursday's Mid-Day Session](https://www.quantisnow.com/insight/38-stocks-moving-in-thursdays-mid-day-session-2179964)
- 2021-12-23 13:24 UTC [Market Insight] [12 Health Care Stocks Moving In Thursday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-thursdays-pre-market-session-2178650)
- 2021-12-23 12:33 UTC [Market Insight] [18 Stocks Moving in Thursday's Pre-Market Session](https://www.quantisnow.com/insight/18-stocks-moving-in-thursdays-pre-market-session-2178435)
- 2021-12-23 11:11 UTC [Market Chatter] [HC Wainwright & Co. Initiates Coverage On Osmotica Pharmaceuticals with Buy Rating, Announces Price Target of $5](https://www.quantisnow.com/insight/hc-wainwright-co-initiates-coverage-on-osmotica-pharmaceuticals-with-buy-2178211)
- 2021-12-23 11:10 UTC [Analyst Coverage Initiated] [HC Wainwright & Co. initiated coverage on Osmotica Pharmaceuticals with a new price target](https://www.quantisnow.com/insight/hc-wainwright-co-initiated-coverage-on-osmotica-pharmaceuticals-with-a-2178210)
- 2021-12-21 12:40 UTC [Market Insight] [4 Penny Stocks Insiders Are Buying](https://www.quantisnow.com/insight/4-penny-stocks-insiders-are-buying-2167854)
- 2021-12-20 22:03 UTC [SEC Form 4] [SEC Form 4: Schaub James bought $100,366 worth of Ordinary Shares (93,800 units at $1.07), increasing direct ownership by 30% to 405,900 units](https://www.quantisnow.com/insight/sec-form-4-schaub-james-bought-100366-worth-of-ordinary-2166185)
- 2021-12-20 21:05 UTC [Conference Announcement] [Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-plc-to-present-at-hc-wainwright-bioconnect-conference-2165367)
- 2021-12-10 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Osmotica Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-effect-filed-by-osmotica-pharmaceuticals-plc-2123656)
- 2021-12-08 21:26 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Osmotica Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-osmotica-pharmaceuticals-plc-2115434)
- 2021-11-17 21:44 UTC [SEC Form 8-K] [Osmotica Pharmaceuticals plc filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-plc-filed-sec-form-8-k-regulation-fd-disclosure-2025002)
- 2021-11-16 22:13 UTC [SEC Form S-8] [SEC Form S-8 filed by Osmotica Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-osmotica-pharmaceuticals-plc-2018880)
- 2021-11-15 22:20 UTC [SEC Form 8-K] [Osmotica Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-plc-filed-sec-form-8-k-results-of-operations-2011493)
- 2021-11-15 21:33 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Osmotica Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-osmotica-pharmaceuticals-plc-2010898)
- 2021-11-15 21:05 UTC [Public Offering] [Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-plc-reports-third-quarter-2021-results-and-provides-2009908)
- 2021-11-15 11:50 UTC [Conference Announcement] [Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-plc-to-present-at-jefferies-london-virtual-healthcare-2005622)
- 2021-11-12 00:30 UTC [Earnings Date] [Osmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-plc-to-provide-third-quarter-2021-business-and-1997968)
- 2021-11-10 21:05 UTC [SEC Form 8-K] [Osmotica Pharmaceuticals plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-plc-filed-sec-form-8-k-leadership-update-financial-1991529)
- 2021-11-09 14:18 UTC [Analyst Coverage Resumed] [Jefferies resumed coverage on Osmotica Pharmaceuticals with a new price target](https://www.quantisnow.com/insight/jefferies-resumed-coverage-on-osmotica-pharmaceuticals-with-a-new-price-1981284)
- 2021-11-08 21:09 UTC [SEC Form 4] [SEC Form 4 filed by Devries Tina Marie](https://www.quantisnow.com/insight/sec-form-4-filed-by-devries-tina-marie-1976319)
- 2021-11-08 21:07 UTC [SEC Form 4] [SEC Form 4 filed by Schaub James](https://www.quantisnow.com/insight/sec-form-4-filed-by-schaub-james-1976284)
- 2021-11-08 21:06 UTC [SEC Form 4] [SEC Form 4 filed by Klein Christopher](https://www.quantisnow.com/insight/sec-form-4-filed-by-klein-christopher-1976263)
- 2021-11-08 21:06 UTC [SEC Form 4] [SEC Form 4 filed by Einhorn Andrew J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-einhorn-andrew-j-1976240)
- 2021-11-08 21:05 UTC [SEC Form 4] [SEC Form 4 filed by Markison Brian A](https://www.quantisnow.com/insight/sec-form-4-filed-by-markison-brian-a-1976227)
- 2021-11-03 20:30 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Osmotica Pharmaceuticals plc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-osmotica-pharmaceuticals-plc-amendment-1955820)
- 2021-10-27 20:22 UTC [SEC Form S-3] [SEC Form S-3 filed by Osmotica Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-osmotica-pharmaceuticals-plc-1923024)
- 2021-10-22 20:27 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Osmotica Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-osmotica-pharmaceuticals-plc-1905820)
- 2021-10-14 20:10 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Osmotica Pharmaceuticals plc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-osmotica-pharmaceuticals-plc-amendment-1876915)
- 2021-10-13 20:45 UTC [Public Offering] [Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-plc-announces-closing-of-35-million-underwritten-public-1872379)
- 2021-10-12 20:46 UTC [SEC Form 8-K] [Osmotica Pharmaceuticals plc filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/osmotica-pharmaceuticals-plc-filed-sec-form-8-k-creation-of-a-1867178)
- 2021-10-08 21:13 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Osmotica Pharmaceuticals plc](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-osmotica-pharmaceuticals-plc-1858607)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/OSMT
- Earnings history: https://www.quantisnow.com/earnings/OSMT
- Dividend history: https://www.quantisnow.com/dividends/OSMT
- Insider transactions: https://www.quantisnow.com/insiders/OSMT
- Options chain: https://www.quantisnow.com/options/OSMT
- SEC 8-K filings only: https://www.quantisnow.com/company/OSMT/8-k
- RSS and alerts for OSMT: https://www.quantisnow.com/docs/rss-feeds.md